News & Updates
Event Calendar
June 17, 2013 - 4:00pm
June 22, 2013 (All day)
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
| Title | Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. |
| Publication Type | Journal Article |
| Year of Publication | 2007 |
| Authors | Karp JE, Smith DB, Levis MJ, Gore SD, Greer J, Hattenburg C, Briel J, Jones RJ, Wright JJ, Colevas DA |
| Journal | Clinical cancer research : an official journal of the American Association for Cancer Research |
| Volume | 13 |
| Issue | 15 Pt 1 |
| Pagination | 4467-73 |
| Date Published | 2007 Aug 1 |
| Abstract | Flavopiridol is a cyclin-dependent kinase inhibitor that is cytotoxic to leukemic blasts. In a phase I study of flavopiridol followed by 1-beta-d-arabinofuranosylcytosine (ara-C) and mitoxantrone, overall response rate for adults with relapsed and refractory acute myelogenous leukemias (AML) was 31%. We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML. |
| Alternate Journal | Clin. Cancer Res. |
Your Support is the Key
Help children like Matthew unlock their potential by becoming a Partner in Potential.
